Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05250843 | TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC | unknown | Phase 2 / Phase 3 | 90 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06081582 | Toripalimab in Combined With Cetuximab,Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC | unknown | Phase 2 | 33 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 13, 2023 |
| clinicaltrials |
| NCT06082557 | A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06078657 | IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) | unknown | Phase 2 | 46 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06080854 | AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer | unknown | Phase 2 | 108 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06060704 | Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | unknown | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT03420014 | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)(FIBROSARC US) | unknown | Phase 2 | 114 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04362722 | Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients(DUNCAN) | unknown | Phase 2 | 40 | Philogen S.p.A.INDUSTRY | 3 | Oct 10, 2023 | clinicaltrials |
| NCT06074484 | A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03616782 | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | unknown | Phase 2 | 98 | Ho Sup LeeOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03697356 | R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia(Ballondor) | unknown | Phase 2 | 54 | Kosin University Gospel HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT05555017 | Tracer-Guided Surgery for Recurrent Prostate Cancer(Trace-II) | unknown | Phase 2 | 60 | The Netherlands Cancer InstituteOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05626829 | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | unknown | Phase 2 | 18 | Jian GuanOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05272462 | Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer | unknown | Phase 2 | 34 | Loyola UniversityOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT06065813 | Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04546074 | Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma | unknown | Phase 1 / Phase 2 | 22 | Keio UniversityOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04591431 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy(ROME) | unknown | Phase 2 | 400 | Fondazione per la Medicina PersonalizzataOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04717674 | [18F]FPIA PET/CT Imaging in Patients With Solid Tumours([18F]FPIA) | unknown | Phase 2 | 21 | University College, LondonOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04754035 | Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia(IMPROVE) | unknown | Phase 2 | 31 | Paolo GhiaOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04856215 | 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia(RITII) | unknown | Phase 2 | 25 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05451173 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | unknown | Phase 1 / Phase 2 | 83 | Alexander ChiOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04726215 | Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer | unknown | Phase 2 | 50 | CellSight Technologies, Inc.INDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT04033107 | High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors | unknown | Phase 2 | 30 | Zhongnan HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04074993 | Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays | unknown | Phase 2 | 35 | JI-YOUN HANOTHER_GOV | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04259944 | Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | unknown | Phase 2 | 140 | IFOM ETS - The AIRC Institute of Molecular OncologyOTHER | 2 | Sep 28, 2023 | clinicaltrials |
| NCT04883814 | 18F-fluoroestradiol (FES) PET/CT for Breast Cancer | unknown | Phase 2 | 124 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05128630 | Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.(DEDALUS) | unknown | Phase 2 | 45 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05174832 | Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients | unknown | Phase 2 | 136 | Fudan UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05728619 | HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 64 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05800834 | Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds(MorphineGEL) | unknown | Phase 2 | 106 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05228496 | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | unknown | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06055166 | A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors | unknown | Phase 2 | 120 | Chongqing University Cancer HospitalOTHER | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06055348 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | unknown | Phase 1 / Phase 2 | 112 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT05296577 | Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer | unknown | Phase 2 | 134 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 25, 2023 | clinicaltrials |
| NCT06051747 | Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea) | unknown | Phase 1 / Phase 2 | 1 | Ja Seong Bae, MD, phDOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT03712956 | CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER | unknown | Phase 2 | 63 | European Institute of OncologyOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04165993 | Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer | unknown | Phase 2 | 68 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05010434 | Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05448820 | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | unknown | Phase 1 / Phase 2 | 15 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05520814 | PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial | unknown | Phase 2 | 50 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05975151 | Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 63 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06018688 | Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. | unknown | Phase 2 | 44 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Sep 21, 2023 | clinicaltrials |
| NCT06046963 | Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites | unknown | Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04492995 | Sentinel Node in Endometrial Cancer(HYBRIDENDONOD) | unknown | Phase 2 | 70 | Judit Pich MartínezOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06041724 | Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma | unknown | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT05353361 | A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer | unknown | Phase 2 | 402 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT06013943 | Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC | unknown | Phase 2 | 30 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05823623 | Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Oct 13, 2023source: clinicaltrials